Bolt Biotherapeutics Inc. (BOLT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago.
Bolt Biotherapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RB Robert Burns HC Wainwright & Co. | 1,097 | $5,427.76 | $5,002.32 | -$425.44 | -7.84% |
Bolt Biotherapeutics Inc. (BOLT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bolt Biotherapeutics Inc. ever had a stock split?
Bolt Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | William Quinn CEO | NASDAQ (CM) Exchange | 097702203 CUSIP |
| US Country | 52 Employees | - Last Dividend | 9 Jun 2025 Last Split | - IPO Date |
Overview
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies aimed at treating cancer. Established in 2015 and based in Redwood City, California, the company has evolved through strategic collaborations and research advancements, initially known as Bolt Therapeutics, Inc. before rebranding to its current name in July 2015. Bolt Biotherapeutics, Inc. operates at the forefront of cancer treatment, focusing on developing effective and targeted therapies to improve patient outcomes. Through its interdisciplinary approach and partnerships with various industry leaders, including Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd, as well as an important license agreement with Stanford University, the company aims to spearhead the discovery and development of next-generation immunotherapies.
Products and Services
- BDC-1001
Bolt Biotherapeutics' flagship product candidate, BDC-1001, is in the clinical development stage, targeting patients with human epidermal growth factor receptor 2-positive (HER2+) solid tumors. These types of tumors are found in various cancers, including breast, colorectal, endometrial, and gastroesophageal cancer. The focus on HER2+ tumors represents a significant part of cancer treatment, as these tumors can be aggressively metastatic and resistant to standard therapies. BDC-1001 embodies the company's commitment to advancing cancer treatment through targeted immunotherapy approaches.
- BDC-3042
The development of BDC-3042, an agonist antibody targeting Dectin-2, signifies Bolt Biotherapeutics, Inc.'s efforts to expand its portfolio to address a wider range of tumors. This innovative approach focuses on engaging the immune system to fight cancers such as head and neck, non-small cell lung, ovarian, triple-negative breast, and various other cancers. The targeting of Dectin-2 is a strategic choice aimed at harnessing the body's inherent immune mechanisms to recognize and eliminate cancer cells, offering potential new avenues for cancer therapy.
